Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3686MR)

This product GTTS-WQ3686MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3686MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1411MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ2217MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ5503MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ3874MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ13275MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ723MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ12558MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ11137MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MDX-1103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW